Article Text
Abstract
Genetic cancer predisposition testing in the paediatric population poses unique ethical dilemmas. Using the hypothetical example of a teenager with cancer with a high probability of having an underlying cancer predisposition syndrome, we discuss the ethical considerations that affect the decision-making process. Because legally these decisions are made by parents, genetic testing in paediatrics can remove a child’s autonomy to preserve his or her own ‘open future’. However, knowledge of results confirming a predisposition syndrome can potentially be beneficial in modifying treatment and surveillance plans and enabling at-risk family members to obtain cascade testing for themselves. Considering virtue ethics to envision the best characters of the patient, parents and healthcare providers can guide them to the better choice to test or not to test, with the ultimate goal of achieving the best outcome for survival and eudaimonia, human flourishing reliably sought out.
- genetic screening/testing
- genethics
- clinical ethics
- paediatrics
Data availability statement
There are no data in this work.
Statistics from Altmetric.com
Data availability statement
There are no data in this work.
Footnotes
Contributors Authors SM and DJK both contributed equally to the research, writing and editing of this manuscript.
Funding Summer URS Ledell Family Research Scholarship for Science and Engineering: UCSD.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes
- Osteonecrosis in patients with acute lymphoblastic leukaemia: a national questionnaire study
- Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia
- CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
- Health care utilisation following childhood acute lymphoblastic leukaemia: a population-based matched cohort study
- Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature
- TP53 c.455C>T p.(Pro152Leu) pathogenic variant is a lower risk allele with attenuated risks of breast cancer and sarcoma
- Multiple primary tumours: challenges and approaches, a review
- UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
- Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort